Latest news with #NIAID
GMA Network
a day ago
- Health
- GMA Network
Ozamiz City logs first mpox case
An undated colorized transmission electron micrograph of mpox virus particles (pink) found within an infected cell (yellow), cultured in the laboratory, captured at the National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility (IRF) in Fort Detrick, Maryland. NIAID/ Handout via REUTERS Health authorities have confirmed the first positive case of mpox in Ozamiz City, Misamis Occidental, Mayor Indy Oaminal said in a press release on Friday, June 20, 2025. The patient, who sought medical attention at the Mayor Hilarion A. Ramiro Sr. Medical Center, is currently in isolation and recovering well. He presented himself voluntarily for a check-up after experiencing symptoms. The City Health Office (CHO) has launched contact tracing efforts immediately to prevent the possible spread of the disease. Individuals identified as close contacts are now being monitored pursuant to the health protocols set by the Department of Health (DOH). Oaminal urged the public not to panic, noting that the Research Institute for Tropical Medicine has confirmed that the mpox strain is Clade II, the milder and self-limiting form of the virus. However, residents are still urged to remain vigilant and report to the nearest health facility if they experience symptoms such as a painful rash, swollen lymph nodes, fever, headache, muscle aches, or back pain. The public is also reminded to practice proper hygiene such as regular handwashing, the use of close-fitting masks in public, and avoiding skin-to-skin contact. "Even if the strain is not deadly, we cannot be complacent. Please remain vigilant and practice the prescribed self-protection measures against the virus. At the first sign of symptoms related to Mpox, immediately proceed to the health facility nearest you," Oaminal said. — GMA Regional TV
GMA Network
15-06-2025
- Health
- GMA Network
DOH: Mpox cases under control, PH not included in WHO public health emergency
An undated colorized transmission electron micrograph of mpox virus particles (pink) found within an infected cell (yellow), cultured in the laboratory, captured at the National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility (IRF) in Fort Detrick, Maryland. NIAID/ Handout via REUTERS Despite the rise of Monkey pox virus (Mpox) cases in the Philippines, the situation is under control and the country is not included in the public health emergency of international concern issued by the World Health Organization (WHO), according to the Department of Health on Sunday. In a report in Super Radyo dzBB, Health Secretary Teodoro Herbosa said that despite the rise of an undisclosed number of local Mpox cases, the number is below figures recorded in the same period in 2024. Mpox cases sa bansa, kontrolado; Pilipinas, hindi kasama sa public health emergency ng @WHO, ayon sa @DOHgovph. #SuperBalitaSaTanghali — DZBB Super Radyo (@dzbb) June 15, 2025 'There is a slight increase of cases in some (local government units) but this is not higher than last year. Mas mataas pa din ang nakita naming cases from last year. We are increasing our campaign in education, treatment and isolation para hindi siya kumalat at dumami pa (to prevent cases from spreading and increasing),' Herbosa said. (The number of cases we observedin 2024 is higher than this year.) Herbosa did not specify the exact locations where the new Mpox cases were reported but said the disease is of the milder Clade II variant compared to Clade I which has a higher mortality rate. Under the Clade II classification, Mpox cases are self-limiting or could heal by itself and does not require close-in intervention from the government. The worldwide emergency covers Clade Ib, the a variant of the Mpox virus that has shown enhanced transmissibility, particularly through close contact and sexual transmission. —RF, GMA Integrated News
Yahoo
07-06-2025
- Politics
- Yahoo
Kash Patel claims ‘breakthrough' in Fauci COVID origins probe
FBI Director Kash Patel said in an interview this week that his agency made a 'breakthrough' as it continues to investigate former National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci, a key player in the U.S.'s early response to the COVID-19 pandemic. At the same time, Patel cautioned Fauci's critics from expecting too much. 'We just had a great breakthrough this week on Fauci,' Patel told podcaster Joe Rogan in an episode of 'The Joe Rogan Experience' released Friday, explaining the FBI had recovered phones used by Fauci early in the pandemic. 'They had always been looking for phones and devices he used while he was back in Trump one [the first Trump administration] during COVID, and nobody had found it until two days ago.' 'Everybody listening to us shouldn't jump to the conclusion [that] everything's in there,' he added. 'Maybe it's deleted, maybe it's not, but at least we found it, and at least now we can tell people that we have been looking because it is of public importance.' President Trump and his allies have long accused Fauci of misleading the government on its handling of the pandemic and hiding the origins of the COVID-19 pandemic. Former President Biden granted Fauci a preemptive presidential pardon before Trump took office in January to shield the retired doctor from prosecution. Trump blasted the move at the time. Sen. Rand Paul (R-Ky.) a year earlier called for Fauci to be jailed over the origins of the COVID-19 virus. Paul and others claim Fauci played a role in the outbreak through lab research in China and accused Fauci of causing 'between 10 [million] and 20 million' deaths from the pandemic. Fauci last year defended himself before the House Select Subcommittee on the Coronavirus Pandemic, arguing that he always followed the best science available and never suppressed evidence of a potential 'lab leak.' He told lawmakers at the time that another million people would have died without government interventions, though he conceded, 'how long you kept them going is debatable.' Biden's pardon covers any offenses from Jan. 1, 2014, to the end of Biden's term related to Fauci's service as NIAID director, a member of the White House's COVID-19 task force or as chief medical adviser to the president. 'We think that there was definite foul play, but my opinion is irrelevant,' Patel said. 'It only matters what I can show the American people and prove.' 'That's what we're working on [but] that's why I don't run out there and say 'Look, we're gonna get this guy, we're 100 percent gonna get him,'' Patel added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
06-06-2025
- Politics
- The Hill
Kash Patel claims ‘breakthrough' in Fauci COVID origins probe
FBI director Kash Patel said in an interview this week that his agency made a 'breakthrough' as it continues to investigate former National Institute of Allergy and Infectious Diseases (NIAID) director Dr. Anthony Fauci, a key player in the U.S.'s early response to the COVID-19 pandemic. At the same time, Patel cautioned that Fauci's critics from expecting too much. 'We just had a great breakthrough this week on Fauci,' Patel told podcaster Joe Rogan in an episode of 'The Joe Rogan Experience' released Friday, explaining the FBI had recovered phones used by Fauci early in the pandemic. 'They had always been looking for phones and devices he used while he was back in Trump one [the first Trump administration] during COVID, and nobody had found it until two days ago.' 'Everybody listening to us shouldn't jump to the conclusion (that) everything's in there,' he added. 'Maybe it's deleted, maybe it's not, but at least we found it and at least now we can tell people that we have been looking because it is of public importance.' President Trump and his allies have long accused Fauci of misleading the government on its handling of the pandemic and hiding the origins of the COVID-19 pandemic. Former President Biden granted Fauci a preemptive presidential pardon before Trump took office in January to shield the retired doctor from prosecution. Trump blasted the move at the time. Sen. Rand Paul (R-Ky.) called a year earlier for Fauci to be jailed over the origins of the COVID-19 virus. Paul and others claim Fauci played a role in the outbreak through lab research in China and accused Fauci of causing 'between 10 and 20 million' deaths from the pandemic. Fauci last year defended himself before the House Select Subcommittee on the Coronavirus Pandemic, arguing that he always followed the best science available, and never suppressed evidence of a potential 'lab leak.' He told lawmakers at the time that another million people would have died without government interventions, though he conceded, 'how long you kept them going is debatable.' Biden's pardon covers any offenses from Jan. 1, 2014, to the end of Biden's term related to Fauci's service as NIAID director, a member of the White House's COVID-19 task force or as chief medical adviser to the president. 'We think that there was definite foul play, but my opinion is irrelevant,' Patel said. 'It only matters what I can show the American people and prove.' 'That's what we're working on (but) that's why I don't run out there and say 'Look, we're gonna get this guy, we're 100 percent gonna get him,'' Patel added.
Yahoo
02-06-2025
- Business
- Yahoo
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The grant will support development of MiNK's allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation (HSCT), in collaboration with the University of Wisconsin. 'This non-dilutive funding from NIAID underscores the growing recognition of iNKT cells as a unique and powerful modality in immune regulation,' said Jennifer Buell, PhD, President and Chief Executive Officer of MiNK Therapeutics. 'The work led by Dr. Gumperz and her team at the University of Wisconsin has provided important mechanistic insights into how allo-iNKT cells may not only prevent graft-versus-host disease (GvHD) but also improve the success of engraftment. Through our preclinical and clinical collaboration, we aim to address the needs of the nearly 50% of patients undergoing allogeneic stem cell transplants who are at risk for this serious and potentially life-threatening complication. This award both validates the promise of our iNKT platform and accelerates its development in a high-priority area of unmet medical need.' GvHD is a severe immune complication that can occur after allogeneic HSCT, often leading to multi-organ damage and high mortality. iNKT cells are uniquely suited for this setting due to their natural ability to regulate immune responses, promote tissue repair, and suppress inflammatory pathways. 'Our partnership with MiNK unites their cutting-edge iNKT manufacturing with our deep expertise in transplant immunology at the University of Wisconsin-Madison,' said Jenny E. Gumperz, PhD, Professor of Medical Microbiology & Immunology, University of Wisconsin School of Medicine and Public Health. 'iNKT cells can calm the destructive allo-immune response that drives GvHD, while preserving the patient's ability to fight infection—a balance current therapies struggle to achieve. NIAID's support allows us to speed this science toward the clinic and, ultimately, give transplant patients a safer path to long-term survival.' About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells, as well as the collaboration between MiNK and Agenus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact917-362-1370 investor@ Media Contact781-674-4428communications@ Gumpertz et al., Harnessing invariant natural killer T cells to control pathological inflammation. Frontiers. 2022. Gumpertz et al., iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts. Life Sciences Alliance. 2021.
